LXEO LEXEO THERAPEUTICS INC

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences:

The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ET

RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at 11:00 AM ET

Bank of America Securities 2024 Health Care Conference on Wednesday, May 15, 2024 at 8:40 AM PT

The events will be webcast live under the tab in the Investors section of our website. Replays of the webcasts will be available on the website following the presentations.

About Lexeo Therapeutics

Lexeo Therapeutics is a New York City-based, clinical stage genetic medicine company dedicated to transforming healthcare by applying pioneering science to fundamentally change how genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease are treated. Using a stepwise development approach, Lexeo is leveraging early proof-of-concept functional and biomarker data to advance a pipeline of cardiovascular and APOE4-associated Alzheimer’s disease programs.

Media Response:

Janine Bogris

(201) 245-6838

Investor Response:

Stephen Jasper

(858) 525-2047



EN
07/05/2024

Underlying

LXEOLEXEO THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on LEXEO THERAPEUTICS INC

 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Op...

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights Closed an oversubscribed $95 million equity financing in March with Q1 2024 cash balance of $195.1 million at quarter-end, expected to provide runway into 2027 Completed in-license agreement with Cornell University for intellectual property rights, including current and future clinical data from an ongoing investigator-initiated trial of AAVrh.10hFXN (LX2006) to support regulatory discussions Interim readout of combined data set of LX2006 at multiple doses anticipated in mid-2024; Lexeo expects to p...

May 9, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

Lexeo Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced that company management will participate in fireside chats at the following investor conferences: The Citizens JMP Life Sciences Conference on Monday, May 13, 2024 at 9:00 AM ETRBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14, 2024 at...

May 7, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics Announces License Agreement to Accelerate Developme...

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Lexeo Therapeutics gains intellectual property rights including current and future clinical data from ongoing Weill Cornell Medicine investigator-initiated trial of gene therapy candidate AAVrh.10hFXN (LX2006) to support regulatory discussions Together with Lexeo Therapeutics’ ongoing study of LX2006, a total of 11 participants have been treated to date; includes patients at treatment durations out to 18-months with no treatment-related serious adverse ev...

April 22, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an A...

Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to LX2006, the company’s AAVrh.10hFXN-based gene therapy candidate for the treatment of F...

April 16, 2024 1 EN
 PRESS RELEASE
Free
LXEO LEXEO THERAPEUT...

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million E...

Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing Lexeo extends runway into 2027 with private placement co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds and Woodline Partners LP NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to ...

March 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch